FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
|
|
|
|
Company dealt in |
AVADEL PHARMACEUTICALS PLC |
|
Class of relevant security to which the dealings being disclosed relate (Note1) |
|
|
Date of dealing |
|
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
|
|
Long |
Short |
||
|
|
Number |
(%) |
Number |
(%) |
|
(1) Relevant securities |
1,381,490 |
(1.41) |
676,779 |
(0.69) |
|
(2) Derivatives (other than options) |
238,434 |
(0.24) |
63,843 |
(0.06) |
|
(3) Options and agreements to purchase/sell |
0 |
(0.00) |
0 |
(0.00) |
|
Total |
1,619,924 |
(1.66) |
740,622 |
(0.76) |
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
|
Class of relevant security: |
Long |
Short |
||
|
|
Number |
(%) |
Number |
(%) |
|
(1) Relevant securities |
|
|
|
|
|
(2) Derivatives (other than options) |
|
|
|
|
|
(3) Options and agreements to purchase/sell |
|
|
|
|
|
Total |
|
|
|
|
3. DEALINGS (Note 3)
(a) Purchases and sales
|
Purchase/sale |
Number of relevant securities |
Price per unit (Note 4) |
|
Purchase |
16 |
|
|
Purchase |
202 |
|
|
Purchase |
1,340 |
|
|
Purchase |
74 |
|
|
Sale |
13 |
|
|
Sale |
13 |
|
|
Sale |
13 |
|
|
Sale |
13 |
|
|
Sale |
13 |
|
|
Sale |
13 |
|
|
Sale |
14 |
|
|
Sale |
12 |
|
|
Sale |
27 |
|
|
Sale |
27 |
|
|
Sale |
12 |
|
|
Sale |
12 |
|
|
Sale |
12 |
|
|
Sale |
12 |
|
|
Sale |
10 |
|
|
Sale |
12 |
|
|
Sale |
1 |
|
|
Sale |
4 |
|
|
Sale |
11 |
|
|
Sale |
9 |
|
|
Sale |
3 |
|
|
Sale |
12 |
|
|
Sale |
13 |
|
|
Sale |
12 |
|
|
Sale |
5 |
|
|
Sale |
5 |
|
|
Sale |
5 |
|
|
Sale |
1 |
|
|
Sale |
4 |
|
|
Sale |
6 |
|
|
Sale |
5 |
|
|
Sale |
3 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
3 |
|
|
Sale |
2 |
|
|
Sale |
3 |
|
|
Sale |
3 |
|
|
Sale |
1 |
|
|
Sale |
2 |
|
|
Sale |
3 |
|
|
Sale |
3 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
1 |
|
|
Sale |
1 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
3 |
|
|
Sale |
3 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
1 |
|
|
Sale |
13 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
3 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
13 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
2 |
|
|
Sale |
3 |
|
|
Sale |
1 |
|
|
Sale |
2 |
|
|
Sale |
1 |
|
|
Sale |
124,288 |
|
|
Sale |
5,094 |
|
|
Sale |
6,905 |
|
|
Sale |
1,405 |
|
|
Purchase (Loan Full Return) |
36,184 |
N/A |
|
Sale (Borrow Partial Return) |
65,000 |
N/A |
|
Purchase (Borrow New) |
25,676 |
N/A |
|
Sale (Loan New) |
25,676 |
N/A |
|
Purchase (Borrow New) |
21,709 |
N/A |
|
Sale (Loan New) |
36,184 |
N/A |
|
Purchase (Loan Partial Return) |
25,676 |
N/A |
|
Purchase (Loan Full Return) |
10,508 |
N/A |
|
Sale (Borrow Full Return) |
21,796 |
N/A |
|
Sale (Borrow Full Return) |
36,184 |
N/A |
(b) Derivatives transactions (other than options transactions)
|
Product name, e.g. CFD |
Nature of transaction (Note 5) |
Number of relevant securities (Note 6) |
Price per unit (Note 4) |
|
CFD |
Reducing a long position |
4,412 |
|
|
CFD |
Increasing a long position |
4,412 |
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
|
Product name,e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 7) |
Exercise price |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 4) |
|
|
|
|
|
|
|
|
(ii) Exercising
|
Product name,e.g. call option |
Number of securities |
Exercise price per unit (Note 4) |
|
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 3)
|
Nature of transaction (Note 7) |
Details |
Price per unit (if applicable) (Note 4) |
|
|
|
|
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
|
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
|
NONE |
Is a Supplemental Form 8 attached? (Note 9) YES
|
Date of disclosure |
|
|
Contact name |
|
|
Telephone number |
+33(1) 4212 1459 / +48(22) 317 4817 |
|
|
AVADEL PHARMACEUTICALS PLC |
|
Nature of connection (Note 9) |
Advisor to Offeree |
SUPPLEMENTAL FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
OPEN POSITIONS (Note 1)
|
Product name,e.g. call option |
Written or purchased |
Number of relevant securities to which the option or derivative relates |
Exercise price (Note 2) |
Type, e.g. American, European etc. |
Expiry date |
|
Swap |
Sold |
84 |
0.0000 |
N/A |
|
|
Swap |
Purchased |
33,762 |
0.0000 |
N/A |
|
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the